About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Omarigliptin

Company: Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders
Mechanism: Mechanism not yet reported
Route: Route not yet reported
Recruiting trials: None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details

Completed NCT NCT01088711

Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004)

Not yet reported Merck Sharp & Dohme LLC 32 participants Est. completion 2010-05-11 Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01217073

A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)

Not yet reported Merck Sharp & Dohme LLC 685 participants Est. completion 2013-04-01 Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01407276

A Study of Omarigliptin (MK-3102) in Participants With Impaired Renal Function (MK-3102-009)

Not yet reported Merck Sharp & Dohme LLC 49 participants Est. completion 2012-03-23 Stand-alone

Type 2 diabetes Other conditions: Chronic Renal Insufficiency
View official trial listing →
Completed NCT NCT01682759

A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)

Not yet reported Merck Sharp & Dohme LLC 751 participants Est. completion 2015-01-26 Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01697592

Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)

Not yet reported Merck Sharp & Dohme LLC 585 participants Est. completion 2014-05-08 Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01698775

A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)

Not yet reported Merck Sharp & Dohme LLC 213 participants Est. completion 2016-01-19 Stand-alone

Type 2 diabetes
View official trial listing →
Terminated NCT NCT01703208

A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)

Not yet reported Merck Sharp & Dohme LLC 4202 participants Est. completion 2017-03-22 Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01703221

Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)

Not yet reported Merck Sharp & Dohme LLC 414 participants Est. completion 2014-04-25 Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01704261

Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)

Not yet reported Merck Sharp & Dohme LLC 307 participants Est. completion 2014-12-23 Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01717313

A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)

Not yet reported Merck Sharp & Dohme LLC 329 participants Est. completion 2015-06-19 Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01755156

A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)

Not yet reported Merck Sharp & Dohme LLC 402 participants Est. completion 2016-03-16 Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT01814748

A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ≥18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)

Not yet reported Merck Sharp & Dohme LLC 203 participants Est. completion 2015-09-14 Stand-alone

Other conditions: Diabetes Mellitus
View official trial listing →
Completed NCT NCT01841697

Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)

Not yet reported Merck Sharp & Dohme LLC 642 participants Est. completion 2014-11-17 Stand-alone

Type 2 diabetes
View official trial listing →
Terminated NCT NCT01863667

A Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027)

Not yet reported Merck Sharp & Dohme LLC 65 participants Est. completion 2014-04-03 Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT02906709

Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039)

Not yet reported Merck Sharp & Dohme LLC 184 participants Est. completion 2018-08-21 Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT03362398

Omarigliptin & Trelagliptin in Twelve Healthy Egyptian Volunteers

Not yet reported British University In Egypt 12 participants Est. completion 2017-11-28 1 site

Type 2 diabetes
View official trial listing →
Status unknown NCT NCT04365907

Omarigliptin in Four Healthy Egyptian Volunteers

Not yet reported British University In Egypt 4 participants Est. completion 2020-05-28 1 site Stand-alone

Other conditions: Healthy Volunteers
View official trial listing →
Status unknown NCT NCT06449235

Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh

Not yet reported Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders 938 participants Est. completion 2025-06 1 site Stand-alone

Other conditions: Type2diabetes
View official trial listing →

Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

ClinicalTrials.gov — NCT06449235

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.